<DOC>
	<DOCNO>NCT00861601</DOCNO>
	<brief_summary>This open label , multi-centre , dose range study ass efficacy , safety pharmacokinetics eltrombopag thrombocytopenic subject chronic liver disease .</brief_summary>
	<brief_title>Phase 2 , Pharmacokinetics Study Eltrombopag Japanese Thrombocytopenic Subjects With Chronic Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Subject agree comply protocol requirement instruction provide sign dated write informed consent . Male female subject , ≥20 year age ( time inform consent ) chronic liver disease . ChildPugh score &lt; =9 . A baseline platelet count &lt; 50,000/mcL . A baseline serum sodium level &gt; 130 mEq/L . Haemoglobin concentration &gt; 8 g/dL , stable least 4 week . A female eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female : Has hysterectomy Has bilateral oophorectomy ( ovariectomy ) Has bilateral tubal ligation Is postmenopausal ( demonstrate total cessation menses longer one year ) Childbearing potential , negative urine and/or serum pregnancy test screening , within 24 hour period prior first dose investigational product use one follow acceptable method contraception : Complete abstinence intercourse . Any intrauterine device ( IUD ) document failure rate le 1 % per year . Doublebarrier contraception ( condom spermicidal jelly , diaphragm spermicide ) . Male partner sterile ( diagnose qualified medical professional ) prior female subject 's study entry sole sexual partner female . Oral contraceptive ( combine ) . Subject physical limitation ingest retain oral medication . Subjects know suspected hypersensitivity , intolerance allergy ingredient eltrombopag tablet . Evidence portal vein thrombosis abdominal imaging ( ultrasound Doppler appropriate magnetic resonance imaging/computed tomography ( MRI/CT ) image technique ) within 3 month start study . History arterial venous thrombosis ( include BuddChiari Syndrome ) , AND ≥ two follow risk factor : hereditary thrombophilic disorder ( e.g . antithrombinIII ( ATIII ) deficiency , etc . ) hormone replacement therapy systemic contraception therapy ( contain oestrogen ) smoking diabetes hypercholesterolemia medication hypertension cancer Human Immunodeficiency Virus ( HIV ) infection . History drug/alcohol abuse dependence within 1 year prior screen . Any disease condition associate current active World Health Organization ( WHO ) Grade 3 4 bleeding . Active infection require systemic antibiotic therapy . Pregnant , nurse mother , woman may pregnant , woman plan become pregnant time study participation . Treatment platelet transfusion within 2 week prior Day 1 . Treatment interferon within 4 week prior Day 1 . Treatment investigational drug within 30 day five halflives ( whichever longer ) precede first dose study medication . History platelet agglutination abnormality . History porphyria . Subjects deem unsuitable study investigator ( subinvestigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>